Treatment of Drug-resistant TB: MDR Guidelines Overview and Current Use of BPaL in the United States

The diagnosis and treatment of drug-resistant TB continues to challenge even the most experienced clinicians equipped with the latest tools and medications. In this session, we will delve into the latest knowledge on drug-resistant TB treatment. Together with the lead author, we will explore the scientific basis behind the 2019 clinical practice guidelines for treatment of drug-resistant TB, differentiate the US recommendations from those issued by WHO, and explore implications for clinical decision-making by our members. The so-called “BPaL” regimen offers hope for an effective all-oral and short regimen for drug-resistant TB, but experience in the United States is very limited. We will share what is currently known about the key drug in this regimen, Pretomanid, and early clinical experience on this largely unmarked path.

NTCA, in partnership with the University of New Mexico’s School of Medicine Office for Continuous Professional Learning, is able to provide AMA PRA Category 1 Credits™, for the live internet activity, and enduring materials credit, for the on-demand recording of the session made available after the live broadcast. 

NTCA, in partnership with Eastern New Mexico University-Roswell, is able to provide continuing education credits for this live internet activity, and enduring materials credit, for the on-demand recording of the session made available after the live broadcast.